Name: MarketsandMarkets ImmunoBio Series USA Edition 2024
Start: 2024-06-20
End: 2024-06-21
Location: Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

WHAT TO EXPECT

Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers.
Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing treatments for individual patients, enhancing efficacy, and minimizing side effects.
Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
Clinical Applications Across Disorders: Delve into biomarker applications in cancer, immunology, neurodegenerative disorders, and cardiovascular conditions for targeted advancements.
Bioinformatics and AI Analysis: Attend workshops and sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
Biomarker-Based Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
Regulatory Frameworks for CDx: Stay updated on current regulatory frameworks for CDx development, facilitating smoother approvals and applications.
Expanding Biomarker Testing Access: Navigate reimbursement landscapes through cross-sector collaborations to widen access to biomarker testing.
Innovative Strategies in CDx Development: Implement new CDx strategies to bring innovative therapies to the clinic, ensuring effective market access in line with global trends.

Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Bhaskarjyoti Sarmah, Associate Scientific Director, Clinical Biomarkers, Moderna	08:55 - 09:00
Keynote Presentation- How to continue running clinical trials in the EU under IVDR: A pharma company’s perspective Lindsay Darling, Director, Companion Diagnostics Portfolio Management & Operations, Regeneron	09:00 - 09:30
Transforming Oncology with Predicine’s Liquid Biopsy Solutions Alexander Kuklin, Vice President CDx and BioPharma Partnerships, Predicine	09:30 - 10:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Richard Dennis, Chief Commercial Officer, Proteome Sciences	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Proteo-metabolomics as a source of predictive biomarkers Samir Hanash, Director, McCombs Institute for Cancer Detection and Treatment, MD Anderson Cancer Center	11:15 - 11:45
Targeted Monoclonal Antibody development for Therapeutic and Diagnostic applications in Oncology. Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. \| Precision Antibody	11:45 - 12:15
Strategic Approaches to Biomarker Integration in Clinical Research Alok Pandey, Vice President, Biomarker & Translational Science, PBL Assay Science	12:15 - 12:45
Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes Tyler Nielsen, Sr Scientist, Oncocyte Corporation	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Biomarkers and Pharmacokinetics of Monoclonal Antibodies Ravinder Singh, Professor of Laboratory Medicine and Pathology, Mayo Clinic	14:15 - 14:45
A Public-Private Consortium for Evaluation of Assays for Non-invasive Tumor Gene Expression Profiling Althea Lang, Scientific Project Manager, Translational Science, Foundation for the National Institutes of Health	14:45 - 15:15
Dissection of the Tumor Microenvironment Using Spatial Transcriptomics and Deep Learning Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Multiplexed cytokine measurements in culture supernatants upon ex vivo stimulation of human PBMCs to assess cellular immune response in vaccine studies Bhaskarjyoti Sarmah, Associate Scientific Director, Clinical Biomarkers, Moderna	16:30 - 17:00
Detection of ADA-bound protein by acid dissociation Yi-Ya Fang, Senior advisor, Eli Lilly and Company	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	08:55 - 09:00
Anchored Immunotherapy as a Better Approach for Delivery of Immuno-oncology Agents Howard Kaufman, President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School	09:00 - 09:30
Landscape change in melanoma immunotherapy. Déjà vu or revolution? Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University	09:30 - 10:00
SanyouBIO One-Stop Solution for Bispecific antibody and ADC Lanye Huang, Business Development Executive/ Senior BD Manager, SanyouBio	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Enhanced Multiplex IHC Technology for Precision Oncology Aurélie Auguste, Director, Translational Data Analysis, Veracyte	11:15 - 11:45
SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	11:45 - 12:15
Development of methylation and mutation panel for colorectal cancer Collin Hudzik, Scientist, EpigenDx	12:15 - 12:45
Next generation translational research platforms for cell therapy in cancer Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
A Novel B7 Checkpoint Axis for Therapeutic Targeting in Cancer Leena Gandhi, Chief Medical Officer, NextPoint Therapeutics	14:15 - 14:45
Immune stimulation of myeloid cells for cancer therapy Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School	14:45 - 15:15
Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors. Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Enhancing TCR-T Activity for Solid Tumors through Synthetic Biology and Gene Editing Allison Drain, Preclinical Development, Affini-T Therapeutics	16:30 - 17:00
Panel Discussions -Adverse Events and Safety Management: Review potential side effects of immunotherapies and best practices for managing them. Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics Rakesh Dixit, CEO, Bionavigen Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie	17:00 - 17:30
Closing Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	17:30 - 17:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio	08:55 - 09:00
Keynote Presentation - Challenges and Strategies in CDx Development for Supporting Clinical Trials for Innovative Medicine David Yu, Director, Precision Medicine and Translational Medicine, Bristol Myers Squibb	09:00 - 09:30
From Assay Development to Commercialization: CDx Strategy in Genetics Medicine Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron	09:30 - 10:00
Research and Startups Combining Biomarkers, Devices and Algorithms for Personalized Diagnosis and Intervention Vaibhav Saini, Senior Commercialization Manager, Northeastern University	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
The Evolving Landscape of Global Deployment of Liquid Biopsy in Enabling Precision Medicine-Driven Biomarker Focused Drug Development Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono	11:15 - 11:45
Clinical decision rule guided cut-point selection for companion diagnostic (CDx) development Wenting Wang, Oncology Biomarker Statistics Team Lead, Sanofi	11:45 - 12:15
Why you should be concerned about sample preanalytics (A.K.A. garbage in, garbage out) Russell Weiner, Head Oncology and Cell Therapy Clinical Biomarker Sciences, Takeda	12:15 - 12:45
Tailored treatments, artificial intelligence, and the next era of Precision Medicine Amanda Acerbi, Precision Medicine Global Director, Janssen	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Operational Strategies for Precision Oncology Trials Ariel Lefkovith, Manager, Biomarker Operations, Repare Therapeutics	14:15 - 14:45
Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives Joseph Ferrara, Chief Strategy Officer, Veranex Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. \| Precision Antibody Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron Amanda Acerbi, Precision Medicine Global Director, Janssen Vaibhav Saini, Senior Commercialization Manager, Northeastern University	14:45 - 15:30
Closing Remarks from the Chairperson Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio	15:30 - 15:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	08:55 - 09:00
Keynote Presentation - Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination. Rakesh Dixit, CEO, Bionavigen	09:00 - 09:30
ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients Allen Feng, Founder and Chief Scientific Officer, HebeCell Corporation	09:30 - 10:00
Polyploid giant cancer cells: the senescent actuators and evil root of cancer recurrence Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes	11:15 - 11:45
Novel antibody-enabled targeted protein stabilization (TPS2) that augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1 Joanne Lim, Associate Director, Immunology, Orum Therapeutics	11:45 - 12:15
Liquid biopsy – a step closer to realizing the power of precision oncology Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie	12:15 - 12:45
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15

SPEAKERS

Richard Dennis

Chief Commercial Officer, Proteome Sciences

Takami Sato

Professor of Medical Oncology Research Director, Thomas Jefferson University

Roger Waltzman

Chief Medical Officer, Indaptus Therapeutics

Leena Gandhi

Chief Medical Officer, NextPoint Therapeutics

Aurélie Auguste

Director, Translational Data Analysis, Veracyte

Samir Hanash

Director, McCombs Institute for Cancer Detection and Treatment, MD Anderson Cancer Center

Joseph Ferrara

Chief Strategy Officer, Veranex

Ravinder Singh

Professor of Laboratory Medicine and Pathology, Mayo Clinic

Russell Weiner

Head Oncology and Cell Therapy Clinical Biomarker Sciences, Takeda

Ginette Serrero

CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody

Joanne Lim

Associate Director, Immunology, Orum Therapeutics

Anu Santhanagopal

Head US Oncology Medical Affairs Strategy, Boehringer Ingelheim

Ariel Lefkovith

Manager, Biomarker Operations, Repare Therapeutics

Vaibhav Saini

Senior Commercialization Manager, Northeastern University

Yi-Ya Fang

Senior advisor, Eli Lilly and Company

Lindsay Darling

Director, Companion Diagnostics Portfolio Management & Operations, Regeneron

Alexander Kuklin

Vice President CDx and BioPharma Partnerships, Predicine

Alok Pandey

Vice President, Biomarker & Translational Science, PBL Assay Science

Allen Feng

Founder and Chief Scientific Officer, HebeCell Corporation

Aaron Goldman

Faculty and Instructor in Medicine, Harvard Medical School

Althea Lang

Scientific Project Manager, Translational Science, Foundation for the National Institutes of Health

Chakravarthy Garlapati

Senior Scientist, (Molecular and Cell Pharmacology), Alkermes

Raluca Budiu-Predoiu

Director, Companion Diagnostics Strategy Lead, , Abbvie

Rakesh Dixit

CEO, Bionavigen

Siamak Tabrizi

Senior Scientist, Immunitas Therapeutics

Howard Kaufman

President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School

Allison Drain

Preclinical Development, Affini-T Therapeutics

Collin Hudzik

Scientist, EpigenDx

Bhaskarjyoti Sarmah

Associate Scientific Director, Clinical Biomarkers, Moderna

David Yu

Director, Precision Medicine and Translational Medicine, Bristol Myers Squibb

Wenting Wang

Oncology Biomarker Statistics Team Lead, Sanofi

Amanda Acerbi

Precision Medicine Global Director, Janssen

Lanye Huang

Business Development Executive/ Senior BD Manager, SanyouBio

Mario Flores

Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

Zheng Feng

Head, Molecular Biomarkers & Genomics, EMD Serono

Melis McHenry

Associate Director, Precision Medicine CDx, Regeneron

Shriya Joshi

Scientist, small molecule drug discovery, Bristol Myers Squibb

Frank Borriello

Founder and CEO, Alloplex Biotherapeutics

Tyler Nielsen

Sr Scientist, Oncocyte Corporation

Christopher Garris

Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School

Grab before it's gone. Avail 30% Instant Discount

ImmunoBio Series USA Edition 2024

Bridging Science, Innovation, and Health for a Better Tomorrow

CO-LOCATED CONFERENCES